Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial

Li, Xiaoke; Zhou, Daoguo; Chi, Xiaoling; Li, Qin; Wang, Li; Lu, Bingjiu; Mao, Dewen; Wu, Qikai; Wang, Xianbo; Zhang, Mingxiang; Xue, Jing-Dong; Li, Yong; Lu, Wei; Guo, Jiao; Jiang, Feng; Zhang, Xinwei; Li, Zhiguo; Yang, Xianzhao; Guo, Hui; Gan, Danan; He, Liyun; Luo, Lin; Zhang, Ludan; Du, Hongbo; Ye, Yongan

doi:10.1007/s12072-020-10097-z

Cited by 14 publications

(11 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, traditional Chinese medicines have unique advantages against CHB, such as better safety profile and lower price 8 . Our preliminary study confirmed the capability and safety of TGYP for improving HBeAg loss after combination with ETV, thereby reducing disease-related risks in long terms 10 . For TGYP, the main components are Chaihu, Diding, Huangqi and Danggui and it is noteworthy that other studies have reported that Huangqi could relieve HBV induced hepatitis by inhibiting NF-κB signaling 15 , and Chaihu could promote HBeAg clearance by inhibiting HBV replication 16 , 17 .…”

Section: Discussionsupporting

confidence: 73%

“…As for CHM prescriptions which contained a comlex compounds, often function with various multi-targeting and synergistic effects. Among CHM, the TiaoGanYiPi formula (TGYP) was used together with entecavir (ETV), and reported better efficacy for CHB treatment in our previous multi-center, double-blind, randomized placebo-controlled trial 10 . And in Chinese medicine theory, CHB is a complex-syndrome disease, and the TGYP is targeting at the core syndrome which is stagnation of Gan and deficiency of Pi qi, and damp-heat in the Gan and Dan 11 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The mechanism of TiaoGanYiPi formula for treating chronic hepatitis B by network pharmacology and molecular docking verification

Cao

Zao

Xue

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

The Chinese herbal formula TiaoGanYiPi (TGYP) showed effective against chronic hepatitis B (CHB) caused by hepatitis B virus (HBV) infection. Hence, we aimed to clarify the mechanisms and potential targets between TGYP and CHB. The active compounds and related putative targets of TGYP, and disease targets of CHB were obtained from the public databases. The key targets between TGYP and CHB were identified through the network construction and module analysis. The expression of the key targets was detected in Gene Expression Omnibus (GEO) dataset and normal hepatocyte cell line LO2. We first obtained 11 key targets which were predominantly enriched in the Cancer, Cell cycle and HBV-related pathways. And the expression of the key targets was related to HBV infection and liver inflammation verified in GSE83148 database. Furthermore, the results of real-time quantitative PCR and CCK-8 assay indicated that TGYP could regulate the expression of key targets including CCNA2, ABL1, CDK4, CDKN1A, IGFR and MAP2K1, and promote proliferation of LO2 cells. In coclusion, we identified the active compounds and key targets btween TGYP and CHB, and found that the TGYP might exhibite curative effect on CHB via promoting hepatocyte proliferation and inhibiting the liver inflammatory processes.

show abstract

Section: Discussionsupporting

confidence: 73%

Section: Introductionmentioning

confidence: 99%

The mechanism of TiaoGanYiPi formula for treating chronic hepatitis B by network pharmacology and molecular docking verification

Cao

Zao

Xue

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…In contrast, traditional Chinese medicines have unique advantages against CHB, such as better safety pro le and lower price 8 . Our preliminary study con rmed the capability and safety of TGYP for improving HBeAg loss after combination with entecavir (ETV), thereby reducing disease-related risks in long terms 10 . For TGYP formula, the main components are Chaihu, Diding, Huangqi and Danggui.…”

Section: Discussionmentioning

confidence: 56%

“…For a long time, Chinese herbal medicines (CHMs) play a crucial role in CHB treatment and show superiority 8,9 . Among CHMs, the Tiao-gan-yi-pi formula (TGYP) was reported with e cacy for CHB treatment, as reported by our previous multi-center, double-blind, randomized placebo-controlled trial 10 . In Chinese Medicine theory, stagnation of Gan and de ciency of Pi qi, and damp-heat in the Gan and Dan, is a compound core syndrome of chronic hepatitis B 11 .…”

Section: Introductionmentioning

confidence: 64%

The molecular mechanism of TiaoGanYiPi formula for treatment of chronic hepatitis B by network pharmacology and molecular docking verification

Cao¹,

Zao²,

Xue³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

The Chinese herbal formula Tiao-Gan-Yi-Pi (TGYP) showed effective against Chronic Hepatitis B (CHB). In this study, we aimed to clarify the mechanisms and potential targets between TGYP and CHB through network pharmacology and molecular docking verification. The compounds of TGYP were identified in the TCMSP and CNKI databases, and their putative targets were predicted through SwissTargetPrediction and STITCH databases. The targets of CHB were obtained from the GeneCards, NCBI Gene, and DisGeNET databases. The above mentioned data were visualized using Cytoscape, and molecular docking showed the relationship between them. The expression of key targets was verified in GEO databases. Hence, we screened out 11 TGYP-related key targets for CHB included ABL1, CASP8, CCNA2, CCNB1, CDK4, CDKN1A, EP300, HIF1A, IGF1R, MAP2K1 and PGR. The key targets were predominantly enriched in the cancer, cell cycle and hepatitis B pathways and involved in the positive regulation of fibroblast proliferation, signal transduction, and negative regulation of gene expression biological processes, and expression of key target genes was related to HBV infection and liver inflammation. Through this newly constructed interaction network between TGYP and CHB, we identified active compounds and targets which could be further used for providing clinical guidance.

show abstract

“…Traditional Chinese herbs have been applied thousands of years for the treatment of human diseases and have drawn growing attention in drug discovery investigation in recent years (12). Suanzaoren, also termed Semen Ziziphi Spinosae (SZS), is the Ziziphus jujuba Mill (13).…”

Section: Introductionmentioning

confidence: 99%

Spinosin Attenuates Osteoclastogenesis Through Suppressing NF-κB by the Activation of Nrf2/HO-1 Signaling in Osteoporosis

Liu

Zhang

2021

Preprint

View full text Add to dashboard Cite

ObjectiveOsteoporosis is a prevalent metabolic skeletal disorder featured by microarchitecture bone injury and excessive osteoclastic activity.Here, we aimed to explore the effect of Spinosin on osteoclastogenesis of osteoporosis.DesignThe receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis model was established in bone marrow macrophages (BMMs) in vitro. The ovariectomy (OVX)-induced bone loss mouse model was constructed in vivo, followed by micro-CT analysis, Histomorphometric analysis, Hematoxylin and Eosin (H&E) and TRAP staining.ResultsOur data showed that the treatment of Spinosin significantly inhibited the TRAP positive osteoclast and bone resorption induced by RANKL in the BMMs. Spinosin significantly reduced the expression of osteoclast-specific factors, including osteoclast stimulatory transmembrane protein (OC-STAMP), dendritic cell-specific transmembrane protein (DC-STAMP), cathepsin K (CTSK), TRAP, c-Fos and nuclear factor of activated T cells cytoplasm 1 (NFATc1)， in the RANKL-treated BMMs. Mechanically, Spinosin was able to inactivate NF-κB by stimulating Nrf2/HO-1 signaling in BMMs. The trabecular space (Tb.Sp), trabecular number (Tb.N), trabecular thickness (Tb.Th), and bone volume to total volume (BV/TV) were inhibited by OVX treatment, and Spinosin could reverse the effect in the bone resorption mouse model. The OVX-induced serum levels of tumor necrosis factor-α (TNF-α) and tartrate-resistant acid phosphatase 5 B (TRAcp5B) were blocked by Spinosin in the mice. Moreover, Spinosin was able to alleviate OVX-induced loss of femur bone and osteoclasts in vivo.ConclusionsIn conclusion, Spinosin attenuates osteoclastogenesis of osteoporosis through inhibiting NF-κB by activating Nrf2/HO-1 expression. Spinosin may serve as the potential candidate for the treatment of osteoporosis.

show abstract

Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial

Cited by 14 publications

References 40 publications

The mechanism of TiaoGanYiPi formula for treating chronic hepatitis B by network pharmacology and molecular docking verification

The mechanism of TiaoGanYiPi formula for treating chronic hepatitis B by network pharmacology and molecular docking verification

The molecular mechanism of TiaoGanYiPi formula for treatment of chronic hepatitis B by network pharmacology and molecular docking verification

Spinosin Attenuates Osteoclastogenesis Through Suppressing NF-κB by the Activation of Nrf2/HO-1 Signaling in Osteoporosis

Contact Info

Product

Resources

About